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Abstract
Aims Uptake of continuous subcutaneous insulin infusion (CSII) by people with diabetes (PwD) in Ireland is low and exhibits 
regional variation. This study explores barriers and facilitators to accessing CSII by adults with Type 1 diabetes mellitus.
Research design and methods A qualitative study employing focus groups with adults with Type 1 diabetes mellitus (n = 26) 
and semi-structured interviews with health care professionals (HCP) and other key stakeholders (n = 21) was conducted. 
Reflexive thematic analysis was used to analyze data, using NVivo.
Results Four main themes comprising barriers to or facilitators of CSII uptake were identified. These included: (1) aware-
ness of CSII and its benefits, (2) the structure of diabetes services, (3) the capacity of the diabetes service to deliver the CSII 
service, and (4) the impact of individuals’ attitudes and personal characteristics—both PwD, and HCP. Each of these themes 
was associated with a number of categories, of which 18 were identified and explored. If the structure of the health-service is 
insufficient and capacity is poor (e.g., under-resourced clinics), CSII uptake appears to be impacted by individuals’: interest, 
attitude, willingness and motivation, which may intensify the regional inequality in accessing CSII.
Conclusions This study identified factors that contribute to gaps in the delivery of diabetes care that policy-makers may use 
to improve access to CSII for adult PwD.
Keywords Type 1 diabetes · Insulin pumps · Continuous subcutaneous insulin infusion · Medical device · Diabetes 
technology · Health-services research · Qualitative research
Introduction
Continuous subcutaneous insulin infusion (CSII) is widely 
used in particular in the pediatric population of people with 
diabetes (PwD) [1] due to its better accuracy in insulin dos-
ing and flexibility in insulin adjustments [1]. While scientific 
evidence supports the use of CSII [2–4], it requires more 
education from the medical team, more intensive follow-up 
and initially more effort from the PwD to gain the optimal 
benefit from the treatment. Some evidence suggests that 
careful selection of potential CSII users is required to ensure 
that the appropriate PwD is offered CSII [5]. A further factor 
to consider is that CSII is more expensive [6]. The therapy 
is reimbursed in many countries [7], nevertheless, uptake 
of CSII therapy varies internationally and regionally, and 
seems not to be determined only by reimbursement strate-
gies [7–10]. Uptake also varies in different age-groups and 
is highest in younger populations [11, 12] probably largely 
because CSII is recommended as a “first choice treat-
ment” for preschool children by the International Society 
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for Pediatric and Adolescent Diabetes [13, 14]. In Ireland, 
for example, uptake is 5-times higher in children, than in 
adults (34.7% vs. 6.8%) [10], but still, significantly lower 
than in the USA, where uptake is similar in adults and chil-
dren (60%), although, as only 76 clinics were involved in the 
T1D Exchange register across the USA, it may not represent 
the national picture [15]. In the Euro Diabetes Index 2014, a 
report comparing the quality of diabetes care across Europe, 
access to CSII in Ireland was assessed as average (between 5 
and 15% of all type 1 diabetes population) compared to Aus-
tria, Finland, France, Germany, Luxembourg, Netherlands, 
Norway, Sweden and Switzerland with uptake of CSII over 
15% [14]. The recently published study on uptake of CSII in 
Ireland suggests that the rate has not changed since then and 
continues to be below 15% in the population (10.5%) [10].
The reasons behind disparity in the international and 
national distribution of CSII are not well explored. Results 
from a national survey of adult diabetes clinics suggest that 
under-resourcing of diabetes services is a major contributor 
to the low uptake in Ireland [16], but the determinants of 
access to diabetes-related technology require further inves-
tigation. Some barriers to uptake may be related to prefer-
ences of PwD [17, 18], or reimbursement strategies [7], as 
well as lack of specific guidelines and policy documents 
[19]. In Ireland, there are no clinical guidelines or recom-
mendations regarding CSII use in adults and the criteria for 
eligibility to commence CSII are neither standardized, nor 
well described as, for example, in the UK NICE guidelines 
[20]. Although full reimbursement is provided, access to 
CSII varies regionally, suggesting that this issue is complex 
and requires further investigation. The lack of a diabetes 
registry and clinical audits in Ireland do not allow for com-
parison between diabetes-related outcomes (for example, 
hemoglobin HbA1c) in areas with better or worse access 
to CSII. Based on an international comparison from 2014, 
control of type 1 diabetes mellitus (T1DM) reported by one 
clinic in Ireland demonstrated room for improvement and it 
is to be expected that this picture would be similar at other 
sites [21]. CSII may have the potential to improve the quality 
of care for type 1 diabetes in Ireland. However, as the uptake 
of CSII remains low in Ireland when compared to interna-
tional evidence, in particular in adults with type 1 diabetes, 
the problem of access to CSII remains, and the aim of this 
study is to explore the barriers and facilitators to accessing 
CSII by PwD in Ireland.
Materials and methods
Qualitative design
This study used a qualitative approach to capture a broad 
range of determinants of uptake of CSII [22]. To gain insight 
from a variety of experiences and opinions, face-to-face 
semi-structured interviews with health care professionals 
(HCP) and other key stakeholders, patient advocates and 
adult PwD across Ireland were conducted. Additionally, 
focus groups with adult PwD in four Irish cities from dif-
ferent geographical areas were performed. Individual inter-
views and focus groups were combined to enhance data 
completeness [23], as well as for pragmatic reasons related 
to the recruitment strategy.
Sampling and recruitment
This study employed purposive sampling, a technique widely 
used in qualitative research to identify and select individu-
als (or groups) that are especially knowledgeable about a 
phenomenon of interest [24]. For individual semi-structured 
interviews, recruitment was guided by respondents’ profes-
sional role (to gain different perspectives), and the level of 
uptake of CSII and experience in CSII (to explore different 
barriers and facilitators in areas of low and high uptake of 
CSII). Some participants (endocrinologists, nurses, dieti-
tians working in diabetes clinics) were recruited during data 
collection for a national survey of the availability of CSII in 
Ireland [16], and some (policy-makers, patient advocates, 
insulin pump company representatives, and those from rural 
areas) through the snowball technique. This method is often 
used to find and recruit “hidden populations” or groups not 
easily accessible to researchers through other sampling strat-
egies. Potential “experts” may be included in the study at the 
suggestion of the interviewees who recommend potential 
key informants [24, 25].
Focus groups were conducted to explore the experi-
ences of PwD from different demographic locations (from 
areas of low, average or high uptake of CSII [9, 10]), and 
of those with an experience of successful access to CSII, 
and those not on CSII. PwD were recruited through online 
social media groups (Facebook, Twitter) and through sup-
port of Diabetes Ireland (the national diabetes-focused char-
ity), Thriveabetes (blog and annual conference for PwD) 
and through local T1DM support groups. Across each area, 
effort was made to recruit a diverse group of participants 
with respect to sex, diabetes duration, place of living (urban 
vs. rural), and technology use. Critical recruitment crite-
ria were: having T1DM, and age over 18. Those who com-
menced CSII before age 18 or outside Ireland were excluded 
from recruitment. To ensure participation of PwD on treat-
ments other than CSII, focus groups attendees were invited 





Interviews and focus groups were conducted between June 
and September 2018 by K.A.G. The same topics (Table 1) 
were discussed in every conversation. Topic guides were 
developed by all co-authors, based on the findings of a lit-
erature review (including conceptual frameworks of access 
to health care [26], technology utilization [27] and existing 
literature about CSII distribution worldwide), and the results 
of the studies on the uptake [9, 10] and availability [16] 
of CSII in Irish diabetes clinics. During each conversation, 
a map of uptake of CSII in Ireland was presented to par-
ticipants and discussed (Appendix S1). Topic guides were 
pretested with one PwD and one HCP.
Data analysis
All focus groups and interviews were recorded, transcribed 
(by K.A.G. or external professional transcribers) and error-
checked for accuracy and consistency. Transcripts were de-
identified (pseudonymized, with access to originals granted 
to K.A.G. only) and analyzed thematically, according to the 
principles of reflexive thematic analysis [28]. All analysis 
was performed by K.A.G., in consultation with co-authors. 
An inductive approach to analysis was used—the analysis 
was data-driven, and conducted according to Braun and 
Clarke’s 6-phases of thematic analysis [22]. After data 
familiarization, three rounds of coding (manual open coding, 
and two rounds of open coding with use of qualitative soft-
ware—NVivo, ver. 12) were conducted. Codes were merged 
into categories and sub-themes and then, based on the cat-
egories, broader overarching themes were generated and 
checked against each other and back to the original dataset. 
Developed themes were named, defined and reported [22]. 
More information about the methodological approach is pro-
vided in Appendix S2. In this report, anonymized quotations 
representing themes and categories are presented, followed 
by an abbreviation of participant group and, if available, the 
area of uptake where the participant works/lives.
The study was approved by the research ethics com-
mittee of the Royal College of Surgeons in Ireland (RCSI, 
REC ref. 1494b) and informed consent was obtained from 
Table 1  Key areas explored and discussed in Interviews with health care professionals and key stakeholders and Focus groups with people with 
diabetes on accessing insulin pump therapy
a While the same general areas, outlined above, were covered with all participants, tailored questions were also asked in particular groups of par-
ticipants, and probes used to encourage and enable a fuller elicitation of responses to particular questions
b HCP health care professionals, OKS other key stakeholders, PwD people with diabetes
No. Topic of  discussiona Respondents
1 Experience
With type 1 diabetes mellitus (T1DM) HCPb,  OKSb,  PwDb
With continuous subcutaneous insulin infusion (CSII) therapy HCP, OKS, PwD
PwD: their diabetes story/background PwD
2 Access to CSII
Exposure to CSII HCP, PwD—those 
not on CSII asked 
first
Decision to commence CSII (How? Who?) HCP, PwD
PwD’s journey to access CSII HCP, OKS, PwD
Criteria HCP, PwD
“Good” pump clinic HCP, OKS, PwD
3 Results of previous studies (Barriers)
Availability of CSII in Irish diabetes clinics (1/3 not providing any CSII services, only 45% pro-
viding training to commence CSII)
HCP, OKS, PwD
Low uptake of CSII (6.8% of adults, 34.7% of children with T1DM on CSII) HCP, OKS, PwD
4 Determinants of uptake
Map of uptake—geographical differences HCP, OKS, PwD
“My area” vs. other areas HCP, PwD
5 What can be done to improve the uptake?
International comparisons HCP, OKS
What policy-makers could do? HCP, OKS, PwD
6 Importance of the access to diabetes-related technology (CSII, CGM, FGM etc.) HCP, OKS, PwD
7 Summary of what has been discussed + additional comments from participants HCP, OKS, PwD
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all participants. Details of the interview/focus group were 
provided in advance and consent was obtained prior to data 
collection. To minimize bias, Standards for Reporting Quali-
tative Research (SRQR) [29] were used to guide the data 
collection and reporting (Appendix S3).
Results
Twenty-one interviews and four focus groups were con-
ducted. The participants (n = 47) included 28 PwD and 19 
HCPs or other key stakeholders (OKS) (Table 2). Inter-
views lasted a median of 62 (range: 45–95) minutes, and 
focus groups lasted for a median of 121.5 (range: 113–141) 
minutes. Discussed topics aligned with four main themes, 
including 18 categories that could be either barriers or facili-
tators, which were developed and integrated into a “Concep-
tual Framework of accessing diabetes-related technology” 
(Fig. 1). The four themes were (from the least frequently 
discussed to the most): awareness, structure, capacity and 
impact of an individual. The brief overview of the categories 
within the themes and the frequency of discussed aspects are 
presented in Tables 3 and 4, respectively. The heterogeneity 
in uptake and unequal access to CSII were described as an 
independent, cross-cutting theme “inequality” that was pre-
sent in all main themes and described the research problem. 
Quotes representing themes are provided in Appendix S4 
in a numerical order. As the topic was complex, all themes 
were interrelated, and some categories may fit into two dif-
ferent themes. The description of the themes and categories 
is based on the qualitative analysis only. The most frequently 
discussed categories within the themes (highlighted in 
Table 4) are described in more detail. Additional analysis of 
comparisons between HCP’s and PwD, as well PwD on CSII 
and not on CSII are provided in more detail in Appendix S5.  
Research problem: inequality
All four themes are influenced by the cross-cutting sub-
theme inequality, and the discussion about inequality in 
accessing CSII was mainly related to a place where PwD 
lives. There was general agreement among participants that 
the uptake of CSII is low in Ireland, and that the “postcode 
lottery“, understood as an unequal provision of services, 
exists. This postcode lottery issues. If you live in the right 
place you get the best care, if you live in the wrong place 
you get screwed (HCP1, high uptake). This disparity was 
“frustrating” for all participants and it was “obvious” that 
low uptake is caused by the lack of local access to CSII: 
participants from these areas have to travel to access care, 
have time to travel and perhaps have to pay for it; thus, it 
requires significant motivation and willingness. In addition, 
the need to travel may limit consultation duration and access 
Table 2  Characteristics of participants of the qualitative study, both 
focus groups and interviews on the barriers and facilitators to access-
ing insulin pump therapy
a “Not applicable” cases are not included in the calculations of the 
percentages
All Participants n (%)
Gender
 Male 20 (43%)
 Female 27 (57%)
Area of CSII  uptakea
 Low 12 (28%)
 Medium 8 (18%)
 High 24 (54%)
 Not applicable 3
Type of  carea
 Public only 29 (66%)
 Private only 11 (25%)
 Public and private 4 (9%)
 Not applicable 3
People with type 1 diabetes
Age group
 18–35 10 (36%)
 36–55 12 (43%)
 56 and over 6 (21%)
Diabetes duration
 0–10 years 5 (18%)
 11–20 years 8 (29%)
 21–30 years 8 (29%)
 30 years and over 7 (25%)
On CSII:
 For up to 2 years 6 (21%)
 3–5 years 6 (21%)
 6 and more (up to 15) 8 (32%)
 Not on CSII 8 (25%)
Traveling to a different county to access care:
 Yes 8 (29%)
 No 20 (71%)
Technology use
 Yes—insulin pump and CGM/Libre 17 (61%)
 Yes—insulin pump only 3 (11%)
 Yes—CGM/Libre only 5 (19%)
 No 3 (11%)
Other key stakeholders
Type of profession:
 DNS/ANP 9 (43%)
 Endocrinologist/diabetologist 6 (29%)
 Dietitians, Company reps, Patient advocates 6 (29%)
Involved in policy-making
 Yes 5 (24%)
 No 16 (76%)
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to education compared to PwD who live close to well-estab-
lished clinics. Their choice of diabetes team or consultant 
is limited, and they have to “fight” much more than PwD 
living in areas where access to CSII, and what they perceive 
as “quality of care”, is more available. You know what it is 
reflecting? The diabetes teams. Your concentration of insu-
lin pump therapy is reflecting the dedication of the diabetes 
teams, or the experience of the diabetes teams, without a 
shadow of a doubt. (OKS 1). (Appendix S4, Q1–Q2). In the 
following, the four main themes, determining this inequality, 
are discussed.
Awareness
Awareness is related to a knowledge, or perception about 
existing diabetes-related technology, available choices, 
options and need for improvement. If people are aware of 
options, if they know that the options exist and how it can 
Fig. 1  Conceptual framework of accessing diabetes-related technology. The main themes and categories that are either barriers or facilitators to 
uptake and availability of insulin pump therapy
 Acta Diabetologica
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Table 3  Themes and categories within the themes: definition
Awareness
Exposure Exposure relates to familiarization with CSII thanks to HCP/MDT (offering/explaining CSII), a 
person on CSII, advert, online discussions (DOC) or events for PwD; HCP may be exposed (or not) 
during their professional training, or involvement/experience in the pediatric diabetes clinics. The 
exposure can be generated thanks to a structure
Education Diabetes education is essential to learn the self-management, carb-counting, it is also an opportunity 
to expose PwD/HCP to CSII; good quality, standardized education is a core of diabetes treatment 
and self-management and essential to provide skills and awareness of existing options; it is a key 
requirement to commence CSII
Information & choice Information about CSII, its benefits, as well as pathways and possibilities to commence it; the choice 
of treatment (as well as a device), is a facilitator, however, the choice of CSII in Ireland is limited; 
this category is also a part of the theme structure
Advocacy Formal “fight” for access, highlighting the gaps and issues, contacting politicians, writing letters 
to hospital managers, organizing support groups, formal complains about the gaps in services 
provision etc.; this category was mainly discussed in a context of what adult PwD could learn from 
parents of children with diabetes, who are more effective in their “fight”
Peer support Through peer support—online or face to face—PwD are getting exposed to CSII, can reach the 
information that was unavailable to them in their diabetes clinics, can learn about therapies, options, 
places to go if interested in accessing technology
STRU CTU RE
Structure & clarity (of the health service) The structure that is related to the clarity, standards of care, continuity of care, established referral 
pathways, access to the private offer and overall transparency, pathways and regulations within the 
health-service
Eligibility criteria Criteria to commence CSII that are not-standardized, contradictory, and non-transparent in Ireland, 
and depend on a HCP preference and training; meeting the medical criteria (i.e., hypo-unawareness) 
is an important facilitator of access, and some PwD "do what they must" to only meet the criteria 
(even deteriorate their diabetes management), thus the medical criteria mandate may limit the 
access
Policy This category was discussed mainly in the context for the need of policy-makers’ involvement and 
drive to improve access to CSII, but also in the context of potential solutions to improve it, reasons 
why “diabetes” is not a priority, and use of research and data to inform the policy-makers
Structure & clarity (of the clinic) Structure of the clinic includes dedicated CSII days, staff members, information leaflets, dedicated 
team, clarity related to the information and the waiting lists (“smokescreen”); this category was also 
discussed within a context of the continuity of care, as if it’s lacking, it was perceived as a barrier; 
this topic is directly associated with clinic’s capacity
CAPACITY
Resources This category was mentioned as one of the main barriers and facilitators of access. Resources relate 
mainly to the number of health care professionals, multidisciplinary team including nurses, dieti-
tians, endocrinologists, and team work and agreement within the team
Capacity of the clinic The capacity related mainly to physical space, facilities in the clinic (i.e., software, computers), 
perceived workload, the support from the hospital management, and cooperation with the insulin 
pump company reps. The involvement of company reps was a facilitator, as they usually provide the 
technical training to commence CSII
Funding Funding was mainly discussed in a context of health care-related costs (i.e., posts for health care 
professionals) rather than reimbursement. The lack of funding for MDT members was perceived as 
one of the main barriers within this theme. As part of this category tender, and local budget (Local 
Health Offices) were discussed
Expertise This category was discussed at the individual level (individual HCP’ expertise in CSII therapy), as 
well as the diabetes team (MDT) expertise. The lack of expertise was the obvious barrier to access-
ing/offering CSII, competence and confidence (parts of the expertise) were perceived as facilitators.
HCP training HCP’s training in CSII was perceived as a facilitator—trained HCPs, if workload permits, were more 
likely to offer CSII to PwD. If HCP’s are not trained it is unlikely that they will offer it to PwD. 
This category included the specialist (endocrinology) training, the advantages and disadvantages of 
the Irish system, the lack of standardized exposure to CSII while in medical training, and the fact 
that other HCPs (GPs etc.) are not aware of CSII, was discussed as a barrier
Acta Diabetologica 
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Table 3  (continued)
INDIVIDUALS
HCP—attitude, interests, beliefs, etc. The impact of individual health care professional was the mostly discussed category either as a 
barrier or facilitator of CSII access and uptake. This included attitudes (toward CSII, diabetes tech-
nology, openness) as well as interest in diabetes (mainly T1DM), and beliefs, such as "CSII is for 
children only", or very time-consuming or complicated vs. “just another way of insulin delivery”. 
The older age of a HCP was perceived as a barrier to CSII uptake
PWD—attitude, interests, beliefs, etc. PwD’s positive attitude toward technology in diabetes, empowerment and just a willingness to com-
mence CSII were the driver of CSII uptake. Those empowered, motivated, interested, and really 
wanting CSII were much more likely to get it, than those not willing to “fight” as for CSII. Of other 
aspects, personal characteristics, and psychological aspects (diabetes distress, burnout, and good 
well-being
Cooperation HCP—PwD This category was mainly highlighted by PwD, as if a HCP does not want to listen to a PwD or 
respect the PwD decision, a PwD may just change the clinic and a HCP. Good and respectful coop-
eration was perceived as a facilitator, whereas the lack of it—as a barrier
Leadership No leadership, no leadership skills, no interest in T1DM, willingness to “bother” with setting up a 
CSII-friendly clinic, as well as no push or encouragement of the PwD to commence CSII from the 
diabetes team was perceived as a barrier to access. “Diabetes champions”, “experts”, leaders who 
are vocal and capable of arranging CSII clinic and those who can influence the health-services 
provision, were assessed as facilitators
Table 4  The frequency 
of discussed categories in 
particular themes, as a whole 
theme, and in a separate context 
of barriers and facilitators
All themes All (%) Barriers (%) Facilitators (%)
(Impact of an) individual 29.64 29.27 29.31
Capacity 27.98 28.67 26.80
Structure 24.06 25.92 21.97
Awareness 18.32 16.15 21.92
CATEGORIES WITHIN the THEMES
AWARENESS
Exposure 37.71 36.33 44.74
Education 29.44 30.66 25.76
Information & choice 12.33 20.31 6.17
Advocacy 15.19 12.70 15.24
Peer support 5.33 0.00 8.10
STRU CTU RE
Structure & clarity (of the health service) 38.76 34.31 43.18
Eligibility criteria 25.20 21.90 28.47
Policy 23.80 28.35 19.30
Structure & clarity (of the clinic) 12.24 15.45 9.05
CAPACITY
Resources 42.97 30.47 54.20
Capacity of the clinic 16.46 16.50 16.42
Funding 15.57 28.60 3.86
Expertise 15.05 12.10 17.71
HCP training 9.95 12.32 7.81
INDIVIDUALS
HCP—attitude, interests, beliefs, etc. 45.53 42.46 48.00
PWD—attitude, interests, beliefs, etc. 34.71 34.59 35.00
Cooperation HCP—PwD 13.57 12.93 3.00
Leadership 6.19 10.02 14.00
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affect their lives and diabetes care, they are more likely to 
ask about and consider them. Exposure and Education were 
the mostly discussed categories of Awareness, among oth-
ers: Information & Choice, Advocacy and Peer Support (see 
Table 4).
Exposure
Awareness about CSII can be raised in many ways—for 
example, through exposure through a HCP/diabetes team 
offering this choice. However, of those participants who 
commenced CSII, fewer than half of the PwD (n = 9 of 20) 
(and from the areas of high uptake only) had heard about 
CSII from their diabetes teams or had been offered it by their 
endocrinologist. Others were “fighting” to commence CSII, 
and were exposed through meeting other PwD on CSII, 
or the diabetes online community (DOC). For some par-
ticipants, attendance at the focus group was the first time to 
meet other people on CSII, or that they heard of CSII. Expo-
sure to other sources—other PwD using CSII, events for 
PwD, face-to-face support groups etc.—is therefore crucial, 
if diabetes teams do not offer technology. In this context, 
online resources through the DOC may be a source of infor-
mation. Whether a PwD will conduct an online research, 
comes down to individual factors (theme described in-depth 
later), and access to a source of information, i.e., internet. 
The category of exposure relates to HCPs also—those from 
the areas of low uptake may not be familiar with CSII, never 
or not much exposed, thus not interested in developing the 
service or skills. This relates to participants’ impression of 
the “quality of care” that is usually associated with offering 
CSII. Beyond its existence, another aspect is the “awareness 
of CSII benefits”. Notably, some focus group participants 
“got encouraged to CSII” by other participants commenting 
on its benefits. Moreover, use of other technologies (e.g., 
Continuous or Flash Glucose Monitoring—CGM or FGM) 
was a facilitator mainly for PwD, both through exposure, 
getting used to having something “attached”; and engaging 
more in their care because of having more clinical informa-
tion (Appendix S4, Q3–Q7).
Education
Diabetes education, in particular access to structured pro-
grams, was an integral part of awareness of technology, and 
a facilitator to its uptake. PwD may learn about different 
treatment options, while attending structured education 
programs provided locally by their diabetes teams. Over-
all, education is crucial to raise “awareness” of options and 
choice, but access to education is an issue in Ireland. That is 
why I want more education, I don’t think patients are aware 
that they are doing a bad job… (HCP1, high uptake). In 
some cases, CSII training is the first time and one reason to 
educate a PwD: That’s to see the diabetic nurses for the carb 
counting, the dietitian and to get taught on how to use the 
pump and how to carb count. Because in 20 years I’ve never 
been taught any of that stuff ever (PwD2, FG, low uptake). 
For some PwD, however, education itself is a key solution 
to improving their diabetes control and may consider CSII 
unnecessary for that reason. According to HCPs discussing 
the map of CSII uptake, areas where uptake is high, are 
usually areas where structured education (e.g., DAFNE—
Dose Adjustment for Normal Eating), is available, and low 
in those, where there is no access to DAFNE (Appendix S4, 
Q8–Q10).
Structure
Structure relates to arrangement and organization within the 
health service and individual clinics. According to partici-
pants, structure, if it existed, was an important determinant 
of access, and, in turn, lack of structure, clarity or transpar-
ency related to information and funding was highlighted as 
a barrier. Why can’t we just have a clear outline? This is the 
structure for access to technology. This is the structure to 
access to the diabetes treatment. Here is how you do it this 
way, and here is why you can’t do it the other way (PwD3, 
FG2, high uptake). Categories that this theme is based on 
include issues specific to the health-service or clinic, as 
well as criteria to commence CSII and policy-making. The 
minority of PwD, however, described their experience of 
accessing CSII as “easy and straightforward”, usually the 
process—due to the lack of structure also—was vague and 
not transparent (Appendix S4, Q11). See Tables 3 and 4 for 
more information.
Structure of the health‑service
All participants agreed that the structure and a clear pathway 
to commence CSII were facilitators to CSII uptake. Ele-
ments of the structure of the Irish health service highlighted 
by participants as “facilitating” were related to structured 
referrals (if CSII was unavailable locally), agreed pathways, 
standardized criteria to commence CSII, and—if it existed—
continuity of care. However, the latter category was mainly 
discussed by PwD and usually mentioned as a barrier. Spe-
cifically, seeing a different HCP at each appointment limits 
conversations around modifications of therapy and hap-
pened often in the public service. Do you actually get to see 
your consultant? Like, in last 6 years, I’ve probably seen 
my consultant once. It was always somebody else (PwD4, 
FG2, high uptake). Some hospitals have a structured agree-
ment that PwD willing to commence CSII can commence it 
publicly elsewhere and continue their follow-up care in the 
local center, but this constitutes a challenge for the receiving 
hospitals and increases their workload. In some areas, public 
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referrals to commence CSII were not available at all. There-
fore, for PwD from these areas (low uptake), commencing 
CSII in a private setting was the only one option. Those PwD 
praised private clinics for their structure: “value for money”, 
quick and clear processes, as well as amount of “time” that 
HCP spend with a PwD, and greater continuity. Notably, 
none of the participants living in the areas of the high uptake 
commenced CSII privately—only those from the areas of 
low and medium uptake, in keeping with unequal access to 
services (Appendix S4, Q12–16). On a clinic-level, structure 
includes availability of information sheets, having dedicated 
T1DM or CSII clinic, clear roles of the multidisciplinary 
team (MDT) members (e.g., a dedicated technology nurse). 
A well-structured pathway includes, i.e., group education 
for T1DM followed by encouragement to consider CSII. 
According to some HCPs and PwD, not all PwD are well-
informed, and their attitudes toward CSII might be biased by 
negative beliefs. This, however, works both ways, as some 
PwD might be dissatisfied with CSII treatment when they 
are only made aware of the benefits. Accurate, reliable, prac-
tical information, and a discussion of the pros and cons of 
CSII should be offered as a “standardized education pack-
age” to every PwD so they can make an informed decision 
whether or not to commence the treatment.
Eligibility criteria to commence CSII
The second most important theme and facilitator of CSII 
uptake related to structure were the “eligibility criteria”—
when a PwD meets them. If not—it was discussed as a bar-
rier. Decision of PwD’ eligibility or suitability to commence 
CSII is usually made by HCP, based on their beliefs, experi-
ence, and certain clinical criteria, which, in Ireland, are not 
unified. Lack of standardization intensifies the “postcode 
lottery”, as this decision then depends on individuals and 
diabetes teams, not the structure, and is perceived as a bar-
rier. I have met so many people who have said, “my diabetes 
is too bad for a pump.” Or I have met people who have said, 
“my diabetes is too good for a pump”. And you are like, how 
can you be too bad or too good? (OKS 2). There was an 
impression, that for those who meet the medical criteria such 
as hypo-unawareness or insufficient diabetes control despite 
MDI, access is easier than for those who have a preference 
toward CSII, for lifestyle reasons. In some cases, PwD “have 
to lie to access CSII” or purposely allow their diabetes con-
trol to deteriorate to meet clinical criteria. I think one of the 
criteria is that you have to have a lot of lows, so I worked 
very hard and craved very hard as well, and there were loads 
of lows involved in my day-to-days. So yes, I came up to it 
fairly fast and after that I think it was three or four months 
after I asked to get the pump (PwD5, FG, medium uptake). 
According to some PwD, a “mandate” to attend structured 
diabetes education program prior to commencing CSII may 
be perceived as a barrier, since availability of such programs 
is limited and the waiting lists in some areas of Ireland are 
long, what makes access to CSII more difficult. (Appendix 
S4, Q17–Q19).
Capacity
Clinics’ capacity, understood as factors associated with (in)
ability to provide CSII, was the second most frequently dis-
cussed theme in the entire dataset and is one of the most 
important determinants of uptake and availability of CSII. 
This includes physical capacity, i.e., having space to pro-
vide education and training to commence CSII, software and 
computers to provide follow-up care, and staff (expertise and 
resources) and time within the constraints of a heavy work-
load to provide the service. The most frequently discussed 
categories were related to resources (Table 3).
Resources
All participants believed that the significant workload and 
understaffing of all groups of HCP is one of the most 
important barriers to access CSII. The presence of a MDT 
including dietitian and dedicated diabetes nurse special-
ist was a facilitator, and having more endocrinologists 
on the team was perceived to increase the chances that 
one of them will be interested in providing CSII. The 
“manpower” was seen as equally important, as individual 
attitudes and interest (see theme “[Impact of an] Indi-
vidual”). Even if a consultant is trained and interested in 
CSII, but operates single-handed, access to CSII might be 
limited by the heavy workload. Furthermore, while lead-
ership and a trained team are important to set up a CSII 
clinic, any loss in resources may temporarily curtail an 
established service and stop the CSII provision: someone 
went off on sick leave or went off on maternity leave, the 
insulin pump list per se would be put on hold (OKS 1, 
Appendix S4, Q22–Q24).
Associated with Resources, Expertise of the MDT mem-
bers in CSII was perceived as essential to provide the train-
ing to commence it. Firstly, HCPs have to be trained in CSII 
(in particular nurses and dietitians), and the skills need to 
be regularly applied for their expertise not to be lost. Some 
HCP may not be exposed to CSII during training and the 
expertise of the endocrinologist is often obtained abroad, 
and reflects a personal interest in T1DM. Secondly, diabe-
tes clinics usually cooperate with company reps who pro-
vide technical training for patients and these links should 
be established. Thirdly, a lack of continuity of care was 
described as a barrier by both HCP and PwD. Fourthly, 
confidence in CSII provision has to come from the expo-
sure to PwD on CSII, as even the best CSII training will not 
be effective if a HCP is not exposed to pumps in clinical 
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practice. Finally, an important part of the capacity is sup-
port from hospital management. To sum up this theme: the 
complexity of diabetes care has increased both in terms of 
the individual but equally in terms of the technology. All of 
these add extra burden to the clinic workload and that does 
not seem to be responded to by the health management (OKS 
3). Overall, it was reported that if there is no capacity, it is 
unlikely that CSII will be advertised or promoted, thus it 
may affect the awareness and exposure to pumps (Appendix 
S4, Q25–Q28).
(Impact of an) individual
The most discussed theme impacting on CSII uptake was 
related to individuals: their interest, passion, leadership 
skills (HCP); empowerment and motivation (PwD); coop-
eration between HCP and PwD. Two separate categories 
related to HCP, and PwD are discussed in more detail, two 
others in Table 4.
Health care professionals (HCP)
HCP’s attitude was the most significant and widely dis-
cussed barrier to or facilitator of access to CSII. According 
to participants, HCP (mainly endocrinologists) “are the gate-
keepers”. If they don’t see the need for pump therapy, then 
it is going to be very challenging for you to get your hands 
on a pump. So, they are a key barrier or facilitator. But my 
understanding is there is a wide variety of attitudes toward 
pump therapy. Some consultants are very supportive and 
others not so much. So, HCP and their attitude toward it as 
gatekeepers is absolutely huge (PwD 6, high uptake). HCP 
who are interested in technology and “happy” to provide 
CSII were described as supportive, committed, and inter-
ested in CSII and T1DM, “willing to keep the doors open”. 
As a specialist who provides diabetes care in Ireland is also 
trained in endocrinology, a lot depends on the personal inter-
est of the HCP. I am not really a diabetes guy, I am more of 
an endocrinology guy (HCP3, high uptake). Specialists who 
are more interested in endocrinology than diabetes were seen 
as less likely to offer CSII. Both, PwD and HCP highlighted 
not only the interest, but also the leadership of a consultant, 
and a “can do attitude” as being a facilitator. It is funny how 
one member of staff can make a difference (OKS 1). Con-
versely, lack of interest in CSII and leadership skills were a 
HCP-related barrier to CSII provision: If a consultant has 
no interest in insulin pump or never trained, or an endocri-
nologist who has no experience in that and has no interest 
in developing it, it will never develop (HCP4, high uptake). 
Some of the reticence to commence CSII could be explained 
by “fear of the unknown”, as well as endocrinologist’s age 
(Appendix S4, Q29–Q32).
People with diabetes (PwD)
Key facilitative features of those accessing technology were: 
persistence, empowerment and motivation. Some HCP sug-
gest that the patient should be the person asking about CSII. 
Many PwD argued that they need to “push”, rather than 
“ask” to access CSII even in areas where uptake is high. 
You ask for a pump, but if you are not coming and scream-
ing, they just put you down on the list, and then… there is a 
“list”. But where is that “list”? On the computer! So I think 
that if you are not really looking for it, and until you are 
not really engaged, they just keep you on “the list” (PwD7, 
FG2, high uptake). There was agreement among all PwD 
in this study that they have to fight to access technology, 
in particular in rural areas. I went into XXX and I was like: 
“it’s as simple as this, I’m not leaving until you give me a 
letter to go to the YYY”. I said “I’m done with injections” 
like (PwD8, FG, low uptake). Other ways of “fighting” 
included: “being vocal”; contacting politicians; involving 
media and government to “push” hospital management. All 
participants agreed, however, that adult PwD were generally 
less effective in advocating for the use of CSII than parents 
of children with diabetes. who were more concerned with 
getting the best available treatment for their child. There was 
a consensus among all participants, that the main barrier to 
CSII from PwD side was lack of willingness to do so or a 
lack of interest in diabetes. Some PwD “don’t want to be 
attached” to anything, or report that CSII does not suit their 
lifestyle and needs, and this preference should be respected. 
The lack of initiative and motivation to consider CSII might 
sometimes be determined by poor empowerment, diabetes 
stigma or even burnout—or that the current treatment just 
satisfies PwD’s current needs and they have no preference 
to commence CSII. Reliable information about CSII should 
be provided to PwD in Ireland to enable them to make an 
informed decision regarding commencing CSII. Other 
aspects of this theme included individual cooperation, and 
the “conjunction” between HCP and PwD was seen as facili-
tator. If there is no cooperation, the only solution PwD saw 
was to “move consultants” and find an individual who is not 
a “gatekeeper” (Appendix S4, Q33–Q37). The differences 
between the HCPs and PwD are presented in Appendix S5.
Discussion
This research reveals multiple factors that impact on the 
uptake and availability of CSII and gives a deeper under-
standing of the complexity in access and how it is affected 
by the health-service delivery. The “Conceptual Framework 
of accessing diabetes-related technology” (Fig. 1) presents 
the factors determining the access. Although reimburse-
ment is offered in Ireland, uptake is low, and this is not 
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only limited by understaffing, or the clinics’ capacity, or 
PwD preference, but by the lack of structure, awareness and 
individual preferences of PwD and HCP. The main finding 
of this study is that if the structure of the health-service is 
insufficient (e.g., lack of standardized criteria or a referral 
pathway) and the quality of care is not standardized, CSII 
not always included in specialist training), and if capacity is 
poor (e.g., under-resourced clinics, lack of expertise), CSII 
uptake appears to be impacted by individuals: their interest, 
leadership skills, willingness and motivation. These factors 
may make the regional differences in accessing diabetes-
related technology and the quality of care more evident. 
According to all participants, adult PwD, HCPs and key 
stakeholders should continue the fight to improve the uptake 
and access to technology by being vocal, and by highlight-
ing the gaps to policy-makers and politicians. There is a 
role to play by the national policy in Ireland that can give 
direction and establish a structure for health care providers, 
improve HCP’ awareness and be a useful tool to improve 
CSII uptake. For example, the pediatric model of care for 
CSII in children under five [30, 31] was highlighted in the 
study as one of the determinants of the higher uptake in 
children. There was consensus that adult T1DM care can 
learn from pediatric care, as the type of diabetes is the same. 
Another facilitator of policy-making was felt to be network-
ing and cooperation between all stakeholders, (HCP, PwD 
and politicians); there was a belief, however, that diabetes 
is not prioritized by politicians in Ireland in part, it was felt 
that it is a consequence of the character of diabetes—that is 
not “painful” or “visible” compared to other conditions, e.g., 
cancer. (Appendix S4, Q20–21).
Despite the issue related to resources (work overload, 
lack of a MDT), that has been considered as a barrier in 
CSII access by the audits in the UK [19], Italy [32, 33] and 
Ireland [16], the most important and frequently discussed 
theme was related to the impact of an individual. Willing-
ness and demand of PwD is an important barrier or facili-
tator, and has been discussed in previous research. Tanen-
baum et al. investigated barriers to device use reported 
by adults PwD in the T1D Exchange registry—the main 
barriers included associated costs and insurance (specific 
to the US), and physical barriers to wearing devices [18]. 
Study of parent-reported barriers highlighted the same—
the physical burden, socio-economic factors (perceived 
financial barriers), and the therapeutic effectiveness of the 
device [17]. A review focusing on the adoption of CSII 
concluded that the barriers to acceptance for the person 
with diabetes “include the tension between the expecta-
tions of the device and the actual experience” and that for 
improved integration, early conversations are needed from 
HCP [34]. These studies, however, investigate the barriers 
when PwD are “offered” a pump by their diabetes teams, 
whereas we state that the main barriers or facilitators are 
more complex, and are more focused on the fact that PwD 
“are not being offered” CSII, for complex reasons. The 
results of T1D Exchange study suggest 60% uptake of 
pumps in 38 adult clinics in the USA [15], which is 5 times 
higher than the 12.5% uptake in 21 Irish clinics that are 
offering training to commence CSII [16] in Ireland. Thus 
“interest of PwD” clearly is not the main barrier in Ireland.
The role of HCP’s attitudes, interest and engagement 
is not usually highlighted as a barrier to CSII. The non-
adoption, abandonment, scale-up, spread and sustainability 
(NASSS) framework—a massive analysis of technology 
implementation frameworks—claims that the “adopter 
system” is important, and that staff’ non-engagement and 
non-adoption play an important role in the implementation 
process of any new treatment or technology use [27]. Our 
findings related to the impact of individual highlights the 
importance of the unification or standardization of HCP’s 
approach to care provision. As reported elsewhere, consist-
ent and relevant information is essential for provision of 
effective diabetes self-management [35]. The recently pub-
lished “Pathway to Choice” (JDRF, 2020) highlights “the 
importance of HCPs in engaging people in technology use” 
as crucial for accessing T1DM technology choices [36].
There was an agreement among participants that the 
findings of this study would apply not only to CSII but 
also to other diabetes-related technology, including CGM/
FGM. The dawn of hybrid closed-loop systems is observed 
[37, 38] and, as research aiming to cure T1DM is not yet 
successful, there is a belief that “technology is the cure” 
for T1DM [39]. If access to pumps is limited, access to 
other technological advance is likely to be limited also.
Limitations of the current study should be noted. Firstly, 
it was conducted in Ireland. Therefore, some of the barriers 
or facilitators might be specific to the Irish health-system. 
Secondly, the data were collected and analyzed by K.A.G., 
who is a diabetes educator (CSII trainer) and a PwD; thus, 
the possibility of a researcher-based bias should be acknowl-
edged. Thirdly, the recruitment was based on social media, 
local support groups, and announcements in diabetes clin-
ics—therefore it has to be acknowledged that all participants 
were already interested and engaged in their diabetes care, 
and that the opinions of those “non-attenders” or those not 
interested in diabetes care, or not actively engaging in DOC 
could be different. The snowball technique and purposive 
sampling used in the interviewees’ recruitment may have 
been subject to bias, but the aim of this qualitative research 
was to get the purposeful, in-depth exploration of HCP 
views/experiences based on the richness of their experience 
and insights, not the “objective”, “common”, or “standard-
ized” approaches used in quantitative studies. The results 
of this qualitative study are subjective views by partici-





To conclude, this study contributes to the scarce evidence 
on access to CSII (or any other complex diabetes technol-
ogy) for adult PwD. Although technological advancements 
in diabetes are well-known and influence the quality of dia-
betes care and the lives of PwD, uptake is limited by lack of 
individual motivation and interest, health system structural 
issues, service capacity, awareness and PwD demand. The 
results of this study may inform HCP and policy-makers 
regarding gaps in the delivery of diabetes care, and sug-
gest solutions to reduce the disparities in health service 
provision in the countries where reimbursement of diabetes 
technology is offered. Such steps may include the devel-
opment of national guidelines, models of care, and struc-
tured approaches to provide equal access to CSII across the 
country.
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